Back to Search Start Over

Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast-like giant cells: A case report.

Authors :
Sasaki, Taro
Kawashima, Hiroyuki
Ariizumi, Takashi
Yamagishi, Tetsuro
Oike, Naoki
Umezu, Hajime
Inagawa, Shyoichi
Hotta, Tetsuo
Endo, Naoto
Ogose, Akira
Source :
Molecular & Clinical Oncology; 2018, Vol. 8 Issue 1, p30-33, 4p
Publication Year :
2018

Abstract

Bone leiomyosarcoma is a rare primary osseous malignant tumor with a high metastatic potential. Similar to other bone sarcomas, high histological grade and tumor stage are predictive of a poor outcome. We herein present our experience with treating a 64-year-old woman with bone leiomyosarcoma accompanied by multiple bone metastases. A biopsy revealed occasional osteoclast-like giant cells. In addition to radiation therapy, the osteoclastogenesis inhibitor denosumab was administered but the patient did not undergo adjuvant chemotherapy or surgery. Good clinical and short-term radiological responses to denosumab have been observed for 2 years. Therefore, denosumab may represent a viable treatment option without the need for adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20499450
Volume :
8
Issue :
1
Database :
Complementary Index
Journal :
Molecular & Clinical Oncology
Publication Type :
Academic Journal
Accession number :
127477290
Full Text :
https://doi.org/10.3892/mco.2017.1489